Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivityMartin Siegemund, Klaus Pfizenmaier|Cell Death and Disease|2012Cited by 67
Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension DomainsMartin Siegemund, Christine Rothe|Frontiers in Pharmacology|2021Cited by 11